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Endoproteolysis of Presenilin 1
and Accumulation of Processed Derivatives In Vivo
Gopal Thinakaran,1, 4, 10 David R. Borchelt,1, 4, 10 factors, including age and inheritance. The majority of
early-onset cases of AD (onset <60 years) are inheritedMichael K. Lee,1, 4, 10 Hilda H. Slunt,4
Lia Spitzer,4 Grace Kim,4 Tamara Ratovitsky,4 as autosomal dominant disorders. To date, mutations
have been identified in three genes that cosegregateFrances Davenport,4 Christer Nordstedt,5
Mary Seeger,6 John Hardy,9 Allan I. Levey,7 with affected members of familial AD (FAD) pedigrees:
the amyloid precursor protein (APP) gene on chromo-Samuel E. Gandy,6 Nancy A. Jenkins,8
Neal G. Copeland,8 Donald L. Price,1, 2, 3, 4 some 21 (Goate et al., 1991; Chartier-Harlin et al., 1991;
Naruse et al., 1991; Mullan et al., 1992; Hendricks et al.,and Sangram S. Sisodia1, 2, 4
1Department of Pathology 1992); the presenilin (PS1) gene on chromosome 14 (St.
George-Hyslop et al., 1992; Sherrington et al., 1995);2Department of Neuroscience
3Department of Neurology and the presenilin (PS2) gene on chromosome 1 (Levy-
Lahad et al., 1995a; Levy-Lahad et al., 1995b; Rogaev4The Neuropathology Laboratory
The Johns Hopkins University School of Medicine et al., 1995). While mutations in APP cosegregate with
Baltimore, Maryland 21205 z19 pedigrees with FAD, mutations in PS1 are causative
5Department of Clinical Neuroscience in 60% of pedigrees with early-onsetFAD (Schellenberg,
Karolinska Institute 1995). At present, 25 missense mutations (Sherrington
S-171 76 Stockholm et al., 1995; Alzheimer’s Disease Collaborative Group,
Sweden 1995; Wasco et al., 1995; Campion et al., 1995; Chapman
6Department of Neurology and Neuroscience et al., 1995; Cruts et al., 1995; Boteva et al., 1996) and
Cornell University Medical College a point mutation upstream of a splice acceptor site that
New York, New York 10021 results in an in-frame deletionof exon 9 (PS1DE9) (Perez-
7Department of Neurology Tur et al., 1995) have been identified in the PS1 gene in
Emory University School of Medicine families with early onset FAD. In addition, two missense
Atlanta, Georgia 30322 mutations in the PS2 gene have been identified in pedi-
8Mammalian Genetics Laboratory grees with FAD of variable onset (Levy-Lahad et al.,
ABL-Basic Research Program 1995b; Rogaev et al., 1995). Neither the normal functions
NCI-Frederick Cancer Research and Development of presenilins nor the mechanism(s)by which FAD-linked
Frederick, Maryland 21701 mutations cause AD have been defined. The absence of
9Suncoast Alzheimer’s Disease Laboratories nonsense or frameshift mutations leading to truncated
Department of Psychiatry PS1/PS2 support the notion that AD is caused not by
University of South Florida loss but by the gain of deleterious functions of mutant
Tampa, Florida 33613 polypeptides. In this regard, conditioned medium from
fibroblasts or plasma of affected members of pedigrees
with PS1/PS2-linked mutations show increased levels
of highly amyloidogenicb-amyloid 1-42(43) species rela-Summary
tive to unaffected family members (Scheuner et al., 1995,
Soc. Neurosci., abstract; Song et al., 1995, Soc. Neu-The majority of early-onset cases of familial Alzhei-
rosci., abstract).mer’s disease (FAD) are linked to mutations in two
PS1 and PS2 share extensive amino acid sequencerelated genes, PS1 and PS2, located on chromosome
identity and are predicted to contain between seven14 and 1, respectively. Using two highly specific anti-
(Sherrington et al., 1995) to nine (Slunt et al., 1995) trans-bodies against nonoverlapping epitopes of the PS1-
membrane domains; the vast majority of mutations oc-encoded polypeptide, termed presenilin 1 (PS1), we
cur within, or immediately adjacent to, potential trans-document that the preponderant PS1-related species
membrane helices. PS1/PS2 are homologous to sel-12,that accumulate in cultured mammalian cells, and in
a C. elegans protein involved in cell signaling mediatedthe brains of rodents, primates, and humans are
by the products of lin-12 and glp-1 receptors, whichz27–28 kDa N-terminal and z16–17 kDa C-terminal
play roles in specifying cell fate (Levitan and Greenwald,derivatives. Notably, a FAD-linked PS1 variant that
1995). PS1/PS2 also have partial sequence similaritylacks exon 9 is not subject to endoproteolytic cleav-
to SPE-4, a component of a specialized Golgi-derivedage. In brains of transgenic mice expressing human
organelle in spermatocytes of C. elegans (L’HernaultPS1, z17 kDa and z27 kDa PS1 derivatives accumu-
and Arduengo, 1992). These latter observations havelate to saturable levels, and at z1:1 stoichiometry,
led to suggestions that PS1/PS2 may be involved in cell-independent of transgene-derived mRNA. We con-
signaling pathways, in protein trafficking or ion channelclude that PS1 is subject to endoproteolytic pro-
function (Sherrington et al., 1995; Slunt et al., 1995; Alz-cessing in vivo.
heimer’s Disease Collaborative Group, 1995).
Introduction Several earlier reports have documented that mRNA
encoding PS1 and PS2 are expressed throughout the
Alzheimer’s disease (AD), the most common cause of brain and peripheral tissues (Sherrington et al., 1995;
dementia in the elderly, is associated with several risk Rogaev et al., 1995; Suzuki et al., 1996; Kovacs et al.,
1996; Sahara et al., 1996). However, information regard-
ing the in vivo expression or localization of PS1 protein10These authors contributed equally to this work.
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has not been available. We generated two antibodies
against nonoverlapping epitopes of PS1, to examine the
expression of PS1 in cultured mammalian cells and in
human, primate, and rodent brain. In addition, we gener-
ated several lines of transgenic mice expressing wild-
type human PS1, and analyzed the expression and me-
tabolism of human PS1 in brains of transgenic mice.
Our studies provide compelling evidence that in brain,
full-length PS1 is subject to endoproteolytic processing,
and that the principal PS1-related species that accumu-
late are N-terminal z27–28 kDa and C-terminal z16–17
kDa polypeptides. Epitope mapping studies reveal that
endoproteolytic cleavage is likely to occur between PS1
amino acids 260–320, a subdomain in which z58% of
FAD-linked missense mutations occur. This region also
includes sequences knownto be deleted in a PS1 variant
that lacks amino acids 290–319 (Perez-Tur et al., 1995).
Moreover, we demonstrate that a full-length form of the
PS1 deletion variant (PS1DE9) accumulates in lympho-
blasts from an individual expressing this variant. Finally,
we demonstrate that in transgenic mice expressing wild-
type human PS1, PS1 derivatives of z27 kDa and z17
kDa accumulate to saturable levels and to z1:1 stoichi-
ometry independent of the steady-state levels of
transgene-derived human PS1 mRNA. These data sup-
portour view that PS1 isnormally subject toendoproteo-
lytic cleavage in vivo.
Results
Characterization of PS1 Expression
in Cultured Cells
To perform biochemical and immunocytochemical anal-
ysis of PS1, we generated a rabbit polyclonal antiserum
termed aPS1Loop elicited against a bacterially pro-
duced fusion protein, GSTHuPS1, which contains amino
acids 263–407 of human PS1. This region corresponds
to the “loop” domain between the predicted sixth and
seventh transmembrane domains (Sherrington et al.,
Figure 1. PS1 Expression and Metabolism in Cultured Mammalian
1995). The sensitivity of PS1Loop antiserum was as- Cells
sessed by immunoblot analyses of various dilutions of Western blot analysis of human PS1 expression in transiently
GSTHuPS1, GST fusion proteins containing the analo- transfected COS-1 cells. COS-1 cells were transfected with plasmid
gous loop segments of mouse PS1 (residues 263–407), vector (Vector) or human PS1 cDNA (PS1). Detergent lysates (25 mg
protein) prepared from these cells were fractionated by SDS–PAGEand human PS2 (residues 269–394). We demonstrated
and analyzed by immunoblotting with PS1Loop antiserum (lanesthat as little as 0.25 ng of human and mouse PS1 fusion
1 and 2) and N-terminal antiserum, Ab14 (lanes 3 and 4). Boundproteins are easily detectable by the aPS1Loop antise-
antibodies were detected by reacting with protein A–HRP. PS1-
rum, and that PS1Loop detected the mouse PS1 loop related polypeptides are marked by arrowheads.
fusion protein at about 43% of the efficiency of human
PS1 loop fusion protein (data not shown). Moreover, we
failed to detect crossreactivity of PS1Loop antiserum seen in untransfected cells (Figure 1, lane 2). Hence, we
inferred that the z17 kDa polypeptide detected by theto the human PS2 fusion protein (data not shown).
Human PS1 is a 467 amino acid polypeptide that con- aPS1Loop antiserum is a truncated form of z43 kDa
full-length PS1. If the latter interpretation were correct,tains between seven to nine predicted transmembrane
helices (Sherrington et al., 1995; Slunt et al., 1995). We we anticipated that an N-terminal, PS1-related fragment
might also accumulate in COS-1 cells. To test this hy-transfected cDNA encoding human PS1 into COS-1
cells, and subjected detergent lysates to Western blot pothesis, we immunoblotted the samples shown in Fig-
ure 1 (lanes 1 and 2) with a polyclonal antiserum, Ab14,analysis with PS1Loop antiserum. In COS-1 cells
transfected with empty pCB6 expression vector, we de- raised against a synthetic peptide corresponding to
N-terminal residues 1–25 of human PS1 (epitope map-tected a z17 kDa aPS1Loop-reactive species (Figure
1, lane 1). In cells transfected with full-length human ping analysis of the Ab14 antiserum revealed that the
antiserum recognizes two principal linear epitopes inPS1 cDNA, we observed a z43 kDa polypeptide and a
modest increase in levels of the z17 kDa polypeptide human PS1: ELPAPLYSYF [amino acids 3–10] and
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Figure 2. Mapping PS1 Endoproteolytic Cleavage
(A) Characterization of the C-terminus of PS1-derived z17 kDa polypeptide. Detergent lysates prepared from a stable human 293 line
transfected with plasmid vector (Vector) or Myc epitope-tagged human PS1 (PS1myc) were immunoprecipitated with MycI antiserum. Aliquots
of detergent lysates (lanes 1 and 2), and Myc immunoprecipitates (lanes 3 and 4) were fractionated by SDS–PAGE and analyzed by immunoblot-
ting with PS1Loop antiserum. Bound antibodies were detected by reacting with protein A–HRP. The z45 kDa full-length PS1myc precursor
is marked by a bracket. The z19 polypeptide derived from PS1myc precursor is marked by an arrowhead.
(B) Schematic depicting the full-length PS1 precursor and derivatives. The epitopes recognized by the N-terminal antiserum Ab14, loop
antiserum PS1Loop, and MycI antiserum are indicated by open boxes. The identity of the C-terminus of the z27 kDa polypeptide and the
N-terminus of z17 kDa polypeptide are not known. The predicted site of endoproteolytic cleavage lies within amino acids 260–320 (marked
by a broken line).
SYFQNAQ [amino acids 9–15]). As expected, we de- z17 kDa endogenous polypeptide (Figure 2A, lane 2).
Notably, while the full-length HuPS1myc precursor ap-tected a z27 kDa Ab14-immunoreactive species in
COS-1 cells transfected with empty expression vector pears to accumulate to high levels, we only observed
low levels of accumulated z19 kDa HuPS1myc-derived(Figure 1, lane 3). Moreover, Ab14 antiserum detected
a z43 kDa full-length human PS1and a modest increase fragment relative to endogenous z17 kDa fragments in
293 cells. At present, it is unclear whether the low levelsin levels of the z27 kDafragment in COS-1 cellsexpress-
ing human PS1 (Figure 1, lane 4). Thus, transiently ex- of accumulated z19 kDa HuPS1myc-derived fragment
is the result of inefficient endoproteolytic cleavage ofpressed human PS1 appears to be endoproteolytically
cleaved to N-terminal and C-terminal z27 kDa and z17 the HuPS1myc precursor or enhanced degradation of
the z19 kDa derivative.kDa fragments, respectively, in COS-1 cells.
Although the N-terminal sequence of the z17 kDa In any event, we subjected lysates of human 293 cells
expressing HuPS1myc to immunoprecipitation analysisaPS1Loop-immunoreactive and C-terminal sequence of
the z27 kDa polypeptides remains to be determined, using a polyclonal MycI antiserum (Lee et al., 1993),
and subjected recovered PS1myc-related derivatives tothe lack of reactivity of the aPS1Loop antiserum with
the z27 kDa N-terminal PS1-derived polypeptide leads immunoblot analysis with PS1Loop antiserum. Both the
z45 kDa full-length HuPS1myc precursor and z19 kDaus to reason that identification of epitopes recognized
by this antiserum might shed some light into the site of derivatives that were immunoisolated with MycI reacted
with PS1Loop antiserum (Figure 2A, lane 4). These re-endoproteolytic cleavage. Epitope mapping analysis of
the aPS1Loop antiserum using overlapping short syn- sults strongly suggest that the z19 kDa HuPS1myc and
(by inference) the endogenous z17 kDa PS1 derivativesthetic peptides showed that the antiserum recog-
nizes four principal linear epitopes in human PS1: contain sequences at the extreme C-terminus of respec-
tive precursors. These studies, taken together with epi-TERESQDTV (residues 320–328), FSEEWE (residues
336–341), GPHRSTP (residues 349–355), and LAGEDPE tope mapping analyses and observed electrophoretic
mobility of the N-terminal fragment lead us to conclude(residues 369–375) (Figure 2B). Hence, we anticipated
that PS1 cleavage occurs N-terminal to amino acid 328. that endoproteolytic cleavage of PS1 occurs in a region
bounded by residues 260–320. A schematic depictingTo examine whether the z17 kDa human PS1-derived
polypeptideextends to the extreme C-terminus, we gen- the antibody epitope recognition sites and postulated
region in which endoproteolytic cleavage is likely to oc-erated human 293 cells stably transfected with a human
PS1 cDNA (pHuPS1myc) modified to encode a c-Myc cur in PS1 is presented in Figure 2B.
Examination of the distribution of FAD-linked PS1 mu-epitope tag at the extreme C-terminus of PS1. Detergent
lysates were prepared from stably transfected cells and tations reveals that z58% of missense substitutions
occur between amino acids 260 and 286. Moreover, aexpression of c-Myc epitope-tagged PS1 cDNA was
analyzed by immunoblotting with PS1Loop antiserum. PS1 variant with a deletion of amino acids 290–319
(DE9), resulting from a splice acceptor mutation up-An endogenous z17 kDa molecule was detected in 293
cells transfected with empty expression vector (Figure stream of exon 9 of the PS1 gene, cosegregates with
affected individuals in a British FAD pedigree, F742A, lane 1). In contrast, immunoblots of extracts from
cells expressing HuPS1myc revealed the presence of a (Perez-Tur et al., 1995). To examine whether the DE9
splice variant is subject to endoproteolytic processing,z45 kDa full-length transgene-derived HuPS1myc and
low levels of a z19 kDa polypeptide in addition to the we used aPS1Loop antiserum in Western blot analysis
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Figure 3. Analysis of the FAD-Linked
PS1DE9 Variant
Detergent lysates were prepared from COS-1
cells transfected with vector (Vector), human
PS1 cDNA (PS1), or PS1 cDNA lacking exon
9 sequences (PS1DE9), and lymphoblastsde-
rived from effected carrier (AC041) or unaf-
fected family member (AC104) of the British
FAD pedigree, F74. Lanes 1–5 represent Coo-
massie blue–stained gel containing 20 mg of
COS-1 cell extracts and 50 mg of lymphoblast
extracts. A parallel gel was transferred to a
nitrocellulose membrane and probed with
PS1Loop antiserum (lanes 6–10). PS1-related
polypeptides were visualized by reacting with
[125I]protein A and signals were quantified by
phosphorimaging. The same membrane was
reprobed with Ab14 antiserum and bound pri-
mary antibody was detected with [125I]protein
A (lanes 11–15). Arrowhead indicates the
PS1DE9 polypeptide expressed in AC041
lymphoblasts.
of cell lysates of lymphoblasts obtained from a carrier the levels of PS1-derivatives accumulate to saturable
levels in vivo is obtained from our studies of transgenicof the mutant PS1 allele and a family member with wild-
type PS1 alleles (Figure 3). Remarkably, we observed mice expressing varying levels of human PS1 (see
below).accumulation of a z40 kDa aPS1Loop-immunoreactive
polypeptide in protein extracts from the affected carrier
(AC041) that comigrated with PS1 E9 transiently ex- Accumulation of PS1 Polypeptides in Brain
To examine the expression of PS1 in mouse, primate,pressed in COS-1 cells. In parallel, we observed an
z50% diminution in levels of the z17 kDa PS1 derivative and human brain, we performed immunoblot analysis of
100 mg of total SDS extracts (Figure 4).As we observedinin extracts from lymphoblasts from the affected individ-
ual relative to lymphoblasts from the noncarrier (AC104). untransfected mouse N2a and COS-1 cells, the PS1-
Loop antiserum specifically reacted with a z16 kDaWestern blot analysis with the N-terminal Ab14 antise-
rum confirmed the presence of full-length z40 kDa polypeptide in mouse brain homogenates, and a z17
kDa polypeptide in monkey and human brain homoge-PS1DE9 variant in the AC041 extracts. Notably, and as
we previously observed in untransfected COS-1 and nates, respectively (Figure 4, lanes 1–3). The z40 kDa
signal seen in the monkey brain homogenate is likely ahuman 293 cells, a full-length z43 kDa species was not
detectable in the lymphoblast samples using aPS1Loop protein compression artifact; it was not detected when
the homogenates were fractionated on 10% SDS–poly-or Ab14 antiserum. In any event, we conclude that the
pathogenic PS1DE9 variant fails to be cleaved either acrylamide gels in which polypeptides in the z27–50
kDa range were resolved (data not shown). Furthermore,because the site of endoproteolytic processing is de-
stroyed or because the conformation of the substrate the z40 kDa signal was not detected with an N-terminal
PS1 antiserum, Ab14 (see below). Using Ab14, we de-is altered as a result of the deletion.
To examine the kinetics by which the z17 kDa poly- tected an z27–28 kDa polypeptide in mouse, monkey,
and human brain extracts (Figure 4, lanes 7–9). The z90peptide is generated from full-length, z43 kDa PS1, we
subjected a pool of stable mouse neuroblastoma (N2a) kDa band observed in blots using either aPS1Loop or
Ab14 is unrelated to PS1, as the signal is also presentcells that constitutively express human PS1 to pulse-
chase/immunoprecipitation analysis. Despite our clear in blots probed with protein A–HRP alone (Figure4, lanes
10–12). Parallel analysis of membrane protein fractionsdemonstration of the biosynthesis of full-length z43 kDa
human PS1, we failed to observe conversion of the z43 prepared from rat olfactory bulb, cortex, hippocampus,
cerebellum, and spinal cord confirmed the presencekDa polypeptide to an z17 kDa aPS1Loop-immunore-
active derivative, even following phosphorimaging anal- of the aPS1Loop-immunoreactive z16 kDa and Ab14-
immunoreactive z28 kDa PS1-derived polypeptidesysis for 3 days (data not shown). At present, there is not
a satisfying explanation for our failure to show conver- (data not shown).
sion of full-length PS1 to the predominant z17 kDa spe-
cies that accumulates in cells. We favor two models to Endoproteolytic Processing of PS1
Is a Bona Fide Cellular Eventexplain our results: the cleavage reaction responsible
for generation of the z17 kDa derivative is rate-limiting, To confirm that the z16 kDa mouse PS1 fragment is
generated in vivo, and not derived by artifactual proteol-or only a fraction of newly-generated fragments accu-
mulate. In the latter model, fragments only accumulate ysis during homogenization, we prepared protein ho-
mogenates from mouse brain in the presence or ab-to a saturable level; excess newly-generated fragments
are rapidly degraded. Further support of the idea that sence of COS-1 cells transiently expressing full-length
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Figure 4. Western Blot Analysis of PS1 Poly-
peptides in Brain
(A) Detection of PS1 polypeptides in brain.
Cortical tissue homogenates (100 mg of pro-
tein) prepared from mouse, monkey, or hu-
man brain (lanes 1–3; 7–12) were fractionated
on 12% SDS gels. For comparison, 0.125–0.5
ng aliquots of GSTHuPS1 fusion protein were
also fractionated in the same gel (lanes 4–6).
Lanes 1–6 show the pattern of immunoreac-
tive proteins detected with aPS1Loop anti-
serum; lanes 7–9 show the pattern of immu-
noreactive proteins detected with Ab14
antiserum; lanes 10–12 show the pattern of
proteins detected without primary antibody
incubation. Bound antibodies were detected
by reacting with protein A–HRP. Results iden-
tical to those shown in lanes 10–12 were ob-
tained when primary antibodies were pre-
incubated with excess GSTHuPS1 fusion
protein (aPS1Loop antiserum) or peptide an-
tigen (Ab14 antiserum). Nonspecific signals
generated by protein A–HRP binding are
marked by asterisks.
human PS1, and subjected these mixtures to immu-
noblot analysis (Figure 5A). PS1Loop detected z16 kDa
and z30 kDa species in mouse brain (Figure 5A, lane
1), and a prominent z42–43 kDa full-length PS1 mole-
cule, as well as a z17 kDa derivative in COS-1 cells
transiently expressing PS1 (Figure 5A, lane 2). We con-
firmed that the z30 kDa species detected in mouse
brain extracts is bound nonspecifically; preincubation
of the PS1Loop antiserum with the GSTHuPS1 loop pep-
tide abolished antibody binding to the z16 kDafragment
in mouse brain (Figure 5B, compare lanes 1 and 3) and
the full-length z43 kDa and z17kDa fragments inCOS-1
cells (compare lanes 2 and 4),with noapparent alteration
in reactivity to the z30 kDa species in mouse brain. In
mixtures of the individual extracts (Figure 5A, lane 3),
we observed bona fide PS1-related z42–43 kDa full-
length and z16 kDa aPS1Loop-immunoreactive spe-
cies. Finally, we examined the fate of transiently ex-
pressed human PS1 following cohomogenization of
mouse brain and COS-1 cells expressing human PS1.
Immunoblot analysis of this mixture failed to reveal deg-
radation of the z42–43 kDa full-length PS1 to z16 kDa
species (Figure 5A, lane 4); the pattern of aPS1Loop-
immunoreactive species was largely indistinguishable
from those seen in mixed extracts (Figure 5A, lane 3).
Hence, we conclude that the production of the z16 kDa Figure 5. PS1 Is Not Degraded during Homogenization
fragment is the result of endoproteolytic clevage of the (A) Mouse brain was homogenized in SDS extraction buffer (see
z42–43 kDa PS1 precursor in vivo, rather than the result Experimental Procedures) in the absence (lane 1) or presence (lane
4) of COS-1 cells transiently transfected with human PS1 cDNA (laneof artificial proteolysis during homogenization.
2). Lane 3 represents polypeptides in brain extract (50 mg) and
COS-1 cell extract (20 mg) that were mixed immediately prior to
Endoproteolytic Processing of Human PS1 electrophoresis. PS1 polypeptides were identified by immunoblot-
ting with PS1Loop antiserum followed by incubation with proteinin Transgenic Mouse Brain
A–HRP.Cultured mammalian cells transfected with full-length
(B) Duplicate blots of mouse brain extract and extracts of COS-1human PS1 cDNA express PS1 polypeptides with an
cells transfected with PS1 cDNA were probed with aPS1Loop anti-apparent mass of z42–43 kDa (Figure 1). To examine
serum (lanes 1 and 2) or PS1Loop antiserum preincubated for 20
the expression and metabolism of human PS1 in vivo, hr with 25 mg/ml fusion protein, GSTHuPS1 (lanes 3 and 4). The z29
we generated transgenic mice that express human PS1 kDa polypeptide bound nonspecifically by aPS1Loop antiserum is
marked by an arrowhead.encoded by human PS1 cDNA transgenes under the
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transgenic animals (Figure 6C), the levels of z17 kDa
polypeptides appeared relatively constant between the
transgenic lines, particularly in those lines which ex-
pressed high levels of human PS1 mRNA. However,
transgenic animals with higher levels of transgene-
derived PS1 mRNA (S8-4>R8-1/H8-4>B8-1) correlated
with the presence of full-length z42–43 kDa human PS1
(Figure 6C), which is consistent with the idea that higher
levels of mRNA lead to increased synthesis of full-length
PS1 precursor.
Notably, the constant level of accumulated human
PS1 derivatives between lines is not an artifact of severe
overaccumulation of human PS1. Although the immu-
noblots appear to show that the z17 kDa human PS1
derivatives are highly overexpressed (Figure 6C), we
demonstrated earlier that the PS1Loopantiserum recog-
nizes human PS1 at z2.3-fold the efficiency of the
mouse PS1 (data not shown). Taken together with addi-
tional immunoblotting studies in which the levels of
mouse z16kDa and human z17 kDaPS1Loop-immuno-
reactive derivatives in nontransgenic and transgenic
mice were quantified (Figure 7C), we have verified that
the human PS1 derivatives accumulate to only z2-fold
higher levels than the mouse PS1 derivatives.
As predicted, we also detected elevated levels of an
N-terminal z27 kDa human PS1 derivative in brains of
transgenic animals using Ab14, specific for epitopes
Figure 6. Transgenic Mice Expressing Full-Length Human PS1 contained within aminoacids 3–15of human PS1 (Figure
cDNA Accumulate z17 kDa Derivatives in Addition to Low Levels
7A, right). To examine the levels of N-terminal z27 kDaof Full-Length Human PS1
derivatives, we performed immunoblots of brain homog-Transgenic mice expressing full-length human PS1 cDNA, under the
enates from one nontransgenic and four transgenic ani-transcriptional control of the murine prion protein promoter, were
mals for quantitation, We compared the immunoblotgenerated as described in Experimental Procedures.
(A) Aliquots (5 mg) of total RNA from 10 different lines of transgenic signals of the fragments with full-length human PS1
mice were subject to Northern blot analysis using a 32P-labeled polypeptide in the S8-4 line (Figure 7A). Whereas an z28
human PS1 cDNA probe and washed under low stringency condi- kDa Ab14-immunoreactive polypeptide was detected in
tions. Membranes were exposed to X-ray film for 5 hr (sufficient to
nontransgenic mouse brain, z27 kDa species accumu-reveal transgene-derived mRNA) or overnight (marked by an aster-
lated to higher levels in each of the transgenic brainisks) to demonstrate the level of transgene-derived mRNA relative
homogenates (Figure 7A, right). Moreover, the level ofto endogenous transcripts.
(B) The blot shown in (A) was stripped, then reprobed with full- z27 kDa derivatives appears to accumulate to a satura-
length 32P-labeled mouse actin cDNA. ble level amongst the highest expressing transgenic
(C) Proteins from the cortex and hippocampus of transgenic mice lines (S8-4, R8-1 and B8-1) (Figure 6C), a result indepen-
were extracted as described in Experimental Procedures. SDS ex-
dent of transgene-derived mRNA or full-length humantracts (60 mg) were subject to Western blot analysis using aPS1Loop
PS1 levels (Figure 7B). In parallel, we performed Westernantiserum and bound primary antibody was visualized by incubation
blot analysis to examine the levels of accumulatedwith protein A–HRP.
C-terminal, aPS1Loop-immunoreactive z17 kDa frag-
ments in brain homogenates of nontransgenic andtranscriptional control of the murine prion protein pro-
transgenic animals (Figure 7A, left). Our studies revealedmoter (D. R. B. et al., unpublished data). The levels of
that the z17 kDa and z27 kDa human PS1 fragmentstransgene-derivedmRNA in brains of progeny from each
in the nontransgenic mouse and each of the transgenicof 10 founder lines was examined by Northern blot analy-
mouse samples accumulate to z1:1 stoichiometry (Fig-sis; relative to the level of endogenous PS1 mRNA, the
ure 7C), irrespective of the level of human PS1 mRNAsteady-state levels of human PS1 mRNA was elevated
or full-length human PS1 (Figure 7B). However, it mustby z10- to 20-fold in the lowest expressing transgenic
be noted that the absolute levels of PS1 fragments inline (A10-1) (Figure 6A). Moreover, six of the lines (B8-1,
nontransgenic animals and transgenic lines cannot beB10-1, E8-1, H8-4, R8-1, and S8-4) expressed even
quantified at the present time. To clarify these latterhigher levels of human PS1 mRNA than line A10-1. Re-
issues, it will be essential to demonstrate that the z17probing the blot with a mouse-actin cDNA confirmed
kDa and z27 kDa derivatives are solubilized and electro-equivalent RNA loading across all samples (Figure 6B).
phoretically transferred to nitrocellulose filter mem-To examine the levels of human PS1 in brains of
branes with identical efficiencies.transgenic animals, we subjected homogenates of cor-
In any event, examination of the relative levels of accu-tex and hippocampus to immunoblot analyses using a
mulated derivatives between transgenic lines offered usaPS1Loop antiserum. Surprisingly, although we ob-
an important insight: whereas the concentration of z17served increased levels of an aPS1Loop-immunoreac-
tive polypeptide of z17 kDa in brain extracts of all nine and z27 kDa derivatives in the lowest expressing W5-1
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Figure 7. Accumulation of N- and C-Terminal
PS1-Derived Fragments in Transgenic Mice
(A) We analyzed 30 mg of SDS extracts from
cortex and hippocampus of selected
transgenic mice by immunoblot analysis with
aPS1Loop and Ab14 antisera. To verify that
immunoreactive signals were in the linear
range of detection, standard amounts of full-
length PS1 polypeptide expressed in COS-1
cells (marked 0.5x, 1x, 2x, 4x, and 8x) were
immunoblotted in parallel. Bound primary an-
tibodies were detected by incubation with
[125I]protein A and autoradiography.
(B) Histogram depicting levels of transgene-
derived mRNA relative to the mRNA level in
the highest expressing line, S8-4. mRNA lev-
els were quantified by phosphorimaging of
the blot shown in Figure 6A.
(C) Histogram depicting the levels of z17 and
z27 kDa polypeptides relative to the amount
of 42 kDa PS1 in S8-4 brain. The bars, which
represent an average of the levels of accumu-
lated fragments in the brains of two animals
from each line, was obtained by phosphorim-
aging.
line are not markedly elevated over the concentration mRNAs are ubiquitously expressed in brain and periph-
eral tissues (Sherrington et al., 1995; Rogaev et al., 1995;of fragments in nontransgenic animals, the concentra-
tion of derivatives in the higher expressing lines reached Kovacs et al., 1996; Suzuki et al., 1996; Sahara et al.,
1996), the normal functions and metabolism of the en-a plateau level that is independent of the steady-state
level of full-length human PS1 (Figure C). The mecha- coded polypeptides, termed presenilins, have not been
elucidated.nism(s) that regulate the accumulation of the z17 kDa
and z27 kDa fragments are presently unknown. We used two highly specific antibodies, generated
against nonoverlapping epitopes of PS1, to examine the
expression and metabolism of PS1 in vivo. The presentReplacement of the z16 kDa Mouse PS1
report documents several exciting new findings. First,Derivative in Transgenic Animals
although PS1 is synthesized as a z42–43 kDa polypep-Our immunoblotting studies of nontransgenic mouse
tide, the preponderant PS1-related species that accu-brain samples using PS1Loop antiserum (Figures 4 and
mulate in cultured mammalian cells and in brains of5A) revealed the presence of a z16 kDa polypeptide;
rodents, primates, humans, and transgenic mice arewe predicted that this fragment represented the mouse
analogof the C-terminal z17 kDa human PS1 derivative.
Curiously, when we compared the pattern of aPS1Loop-
immunoreactive species in brain homogenates from
nontransgenic (Figure 8, lane 3) and transgenic animals
(Figure 8, lanes 1 and 2), we discovered that the z16
kDa polypeptide was no longer detectable in transgenic
brain extracts; failure to detect the z16 kDa species is
not the result of our inability to resolve the human PS1
z17 kDa and z16 kDa fragments, since both fragments
are clearly detected in a mixture of nontransgenic and
transgenic brain extracts (Figure 8, lane 4). These stud-
ies further support our view that the z16 kDa fragment in
nontransgenic mice is derived by processing of mouse
PS1, and that the consequence of overexpressing hu-
man PS1-related z17 kDa species is to mitigate the
production, or enhance turnover, of the endogenous
Figure 8. Replacement of the Endogenous z16 kDa C-Terminal
aPS1Loop-immunoreactive fragment. Fragment by Human PS1-Derived z17 kDa Fragment
SDS extracts from nontransgenic (lane 3) and two lines of transgenic
mice (lanes 1 and 2) (100 mg each) were fractionated on 15% poly-Discussion
acrylamide gels and subject to immunoblotting with PS1Loop anti-
serum. Analysis of a mixture of extracts from nontransgenic brainThe great majorityof early-onset cases of FAD are linked
(50 mg) and line B8-1 (50 mg) demonstrates that the endogenous
to mutations in two related genes, PS1 and PS2, located z16 kDa PS1 derivative can be resolved from the human z17 kDa
on chromosomes 14 and 1, respectively. Although re- human PS1 derivative (lane 4). However, extracts from transgenic
brains lack the endogenous z16 kDa derivative.cent studies have demonstrated that PS1 and PS2
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To construct a PS1 expression plasmid transcriptionally depen-z27–28 kDa N-terminal and z16–17 kDa C-terminal de-
dent on the mouse prion protein promoter, we initially obtained arivatives. Epitope mapping studies suggest that PS1
modified murine prion protein (PrP) genomic fragment in Bluescriptis cleaved within a region encompassing amino acids
KS1, designated phgPrP (Fischer et al., 1996; obtained from Drs.
260–320, a region in which over 58% of identified FAD- Marek Fischer and Charles Weissmann, Institute for Molecular Biol-
linked PS1 mutations occur. Notably, we demonstrated ogy, University of Zurich, Switzerland). The phgPrP fragment con-
tains z6 kb of sequences upstream of the predominant PrP tran-that an FAD-linked PS1 variant that lacks amino acids
scription initiation site(s), the first noncoding exon, first intron, and290–319 (PS1DE9) fails to be cleaved. At present, it is
the coding region of murine PrP fused to the second exon and z3unclear whether the entire spectrum of FAD-linked mis-
kb of PrP 39 untranslated sequences. We modified the phgPrP vectorsense mutations have effect(s) on the endoproteolytic
further by replacing the entire PrP open reading frame with a unique
processing of PS1 or the accumulation of PS1 deriva- XhoI site (D. R. B. et al., unpublished data; Scott et al., 1992) to
tives. Those mutations that occur distal to the cleavage generate MoPrP.Xho. A full-length human PS1 cDNA flanked by
XhoI sites was subsequently inserted into XhoI-digested MoPrP.Xhosite (i.e., in the N-terminal 160 amino acids or the
to generate MoPrP.PS1.C-terminus of the hydrophilic loop), would not be pre-
dicted to compromise cleavage of PS1, thus arguing
Fusion Proteinsagainst a general pathogenic mechanism that involves
Glutathione S-transferase (GST) fusion protein constructs were gen-
alterations in endoproteolytic cleavage of the precursor. erated as follows: sequences that encode residues 263–407 of hu-
Second, our transgenic mice studies demonstrate that man PS1 were amplified by PCR using the primer pair 59-CCGGG
the accumulation of z17 kDa and z27 kDa human- ATCCTGTCCGAAAGGTCCG-39 and 59-CCGGAATTCTCAGGTTGT
GTTCCAGTC-39 using human PS1 cDNA as the template; se-specific PS1 derivatives in brain is saturable and dispro-
quences that encode residues 269–394 of human PS2 were ampli-portionate to the levels of transgene-derived mRNA or
fied using the primer pair 59-CCGGGATCCTGTCCCAAAGGGfull-length human PS1. Finally, the stoichiometry of ac-
CCT-39 and 59-CCGGAATTCTCAGGCCACGAAGCAGGC-39 and hu-
cumulated z17 kDa and z27 kDa human PS1 fragments man PS2 cDNA as template; sequences that encode residues 263–
is z1:1 in nontransgenic brain and each of the trans- 407 of mouse PS1 wereamplified using the primer pair 59-CCGGGAT
genic mouse brain samples, and this ratio is indepen- CCTGTCCCAAAGGCCCA-39 and 59-CCGGAATTCTCAGGTTGTGTT
CCAGTC-39 and mouse PS1 cDNA as template. PCR products weredent of the levelof transgene-derived human PS1mRNA
cloned into the BamHI and EcoRI sites of the vector pGEX-2T (Smithexpression. Since our immunoblotting studies con-
and Johnson, 1988). Resulting plasmids encoded fusion proteins offirmed that the human PS1 derivatives accumulate to
GST and the hydrophilic loop domain between the predicted sixth
only z2-fold higher levels than the endogenous mouse and seventh transmembrane domains (Sherrington et al., 1995) of
PS1 derivatives, we argue that this result is not an arti- human PS1 (GSTHuPS1), human PS2, and mouse PS1. The GST
fact of hyperaccumulation of human PS1. fusion proteins were expressed in bacteria andfractionated by SDS–
polyacrylamide gel electrophoresis (SDS–PAGE). Protein concentra-The mechanism(s) involved in regulating the levels
tion of the z43 kDa fusion proteins were determined by comparisonof accumulated PS1-derivatives remains to be estab-
of Coomassie Blue staining of various dilutions of each fusion pro-lished. Although several alternative mechanisms might
tein and known amounts of bovine serum albumin.
be entertained, we propose two scenarios to accommo-
date our findings: the cleavage reaction responsible for Antibodies
generation of the PS1 derivatives is rate-limiting; or, the We utilized two antibodies specific for PS1 in this study: aPS1Loop
fragments only accumulate to a saturable level where- is a polyclonal antiserum elicited in New Zealand White rabbits
following immunization with polyacrylamide gel-purified human PS1in excess newly-generated fragments are rapidly de-
loop fusion protein, GSTHuPS1, and Ab14 is a rabbit polyclonalgraded.
antiserum raised against a synthetic peptide encompassing resi-
dues 1–25 of human PS1 (M. S. and S. E. G., unpublished data).Experimental Procedures
For epitope mapping studies, we synthesized overlapping small
peptides on a cellulose membrane support, as described by FrankGeneration of PS1 Expression Vectors
(1992). For example, to map PS1Loop antiserum, we synthesizedA cDNA encoding human PS1 was generated as described (Slunt
peptides corresponding to PS1 amino acids 263–272, 264–273, 265–et al., 1995). Mouse PS1 cDNA and human PS2 cDNA (Sherrington
274, etc. (a total of 136 peptides). Each membrane was subject toet al., 1995; Levy-Lahad et al., 1995b) were generated by polymerase
Western blot analysis with the appropriate antiserum. Myc epitope-chain reaction (PCR) from reverse-transcribed adult human brain
tagged human PS1 was immunoprecipitated using a polyclonal anti-RNA. Full-length cDNAs were cloned as KpnI–XbaI fragments into
serum Myc-I raised against the synthetic peptide MEQKLISEEDLNBluescript KS(1) (Stratagene, La Jolla, CA) and sequenced using
(Lee et al., 1993). For Western blotting studies of cultured cell andSequenase (USB, Cleveland, OH) in their entirety. Finally, cDNAs
brain extracts, nitrocellulose membranes containing transferredwereexcised from Bluescript KS1 and subcloned into a CMV-based
proteins were incubated with 1:1000 dilution of a PS1Loop or Ab14mammalian expression vector, pCB6 (a gift from Dr. Mike Stinski,
antisera, and bound primary antibodies were detected by bindingUniversity of Iowa, Iowa City, IA), previously digested with KpnI and
with horseradish peroxidase-conjugated protein A (protein A–HRP)XbaI. To generate cDNA encoding a Myc epitope-tagged human
(Sigma, St. Louis, MO) and chemiluminescence detection (Pierce,PS1, the antisense primer used in PCR contained sequences com-
Rockford, IL). For quanitative immunoblotting studies, bound anti-plementary to a region of the c-Myc oncoprotein and residues 462–
bodies were detected by incubation of blots with [125I]protein A467 of human PS1. To generate an expression construct containing
(Dupont/NEN, Wilmington, DE). Bound radioactivity was quantifiedthe FAD-linked human PS1 variant lacking amino acids 290–319
using phosphorimaging technology (Molecular Dynamics, Sunny-(PS1DE9), we isolated cytoplasmic RNA from an EBV-transformed
vale, CA).lymphoblast line from an affected carrier (AC041; see below), and
subjected this preparation to RT-PCR with primers flanking exon 9.
Transfection/Immunoprecipitation AnalysisThe PCR product was digested with PflMI and BbsI, and a 384 bp
and Protein Extractionsfragment was isolated and subcloned into the PflMI–BbsI sites of
African green monkey kidney (COS-1) cells were cultured in Dulbec-a Bluescript KS1 vector containing human PS1 cDNA (Slunt et al.,
co’s modified Eagle’s medium (DMEM) supplemented with 10%1995). The insert was sequenced to confirm the deletion. Subse-
fetal bovine serum in 60 mm2 dishes and transfected with 10 mg ofquently, the entire full-length PS1DE9 insert was excised with KpnI
and XbaI and subcloned into the pCB6 vector above. supercoiled plasmid DNA double banded on CsCl-EtBr gradients.
Endoproteolytic Cleavage of Presenilin 1
189
Cells were lysed 36 hr after transfection in a buffer containing prote- the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 USC Section 1734ase inhibitors and 0.5% SDS (Sisodia et al., 1990) (detergent buffer)
and briefly sonicated. We fractionated 25 mg aliquots by SDS–PAGE solely to indicate this fact.
without prior heating of samples. Fractionated proteins were elec-
trophoretically transferred to nitrocellulose membranes and immu- Received April 15, 1996; revised June 11, 1996.
noblotted with aPS1Loop or Ab14 antisera.
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